Skip to main content

Drug Interaction Potentiation

3
Pipeline Programs
7
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 4 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
LEO 32731Phase 11 trial
Active Trials
NCT03126578Completed32Est. Oct 2017
Star Therapeutics
Star TherapeuticsCA - South SF
1 program
1
MidazolamPhase 11 trial
Active Trials
NCT03493698Completed17Est. Aug 2018
F-star Therapeutics
F-star TherapeuticsUK - Cambridge
1 program
1
MidazolamPhase 1
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
elbasvir/grazoprevirN/ASmall Molecule
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
elbasvir/grazoprevirN/ASmall Molecule
MSD
MSDIreland - Ballydine
1 program
elbasvir/grazoprevirN/ASmall Molecule1 trial
Active Trials
NCT03706222Completed400Est. Feb 2019
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
1 program
Mifepristone 300 MGPHASE_11 trial
Active Trials
NCT03259542Completed33Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Star TherapeuticsMidazolam
Corcept TherapeuticsMifepristone 300 MG
Leo PharmaLEO 32731
MSDelbasvir/grazoprevir

Clinical Trials (4)

Total enrollment: 482 patients across 4 trials

NCT03493698Star TherapeuticsMidazolam

A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

Start: May 2018Est. completion: Aug 201817 patients
Phase 1Completed
NCT03259542Corcept TherapeuticsMifepristone 300 MG

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

Start: Aug 2017Est. completion: Dec 201733 patients
Phase 1Completed
NCT03126578Leo PharmaLEO 32731

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

Start: May 2017Est. completion: Oct 201732 patients
Phase 1Completed
NCT03706222MSDelbasvir/grazoprevir

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

Start: Oct 2018Est. completion: Feb 2019400 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.